Physician Perspectives on Deprescribing Cardiovascular Medications for Older Adults.
Aged
Cardiologists
/ psychology
Cardiovascular Agents
/ therapeutic use
Cardiovascular Diseases
Chronic Disease
Cross-Sectional Studies
Deprescriptions
Drug-Related Side Effects and Adverse Reactions
Female
Frail Elderly
Geriatricians
/ psychology
Humans
Life Expectancy
Male
Surveys and Questionnaires
United States
cardiovascular medications
deprescribing
polypharmacy
variation in care
Journal
Journal of the American Geriatrics Society
ISSN: 1532-5415
Titre abrégé: J Am Geriatr Soc
Pays: United States
ID NLM: 7503062
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
11
06
2019
revised:
06
08
2019
accepted:
07
08
2019
pubmed:
12
9
2019
medline:
15
8
2020
entrez:
12
9
2019
Statut:
ppublish
Résumé
Guideline-based management of cardiovascular disease often involves prescribing multiple medications, which contributes to polypharmacy and risk for adverse drug events in older adults. Deprescribing is a potential strategy to mitigate these risks. We sought to characterize and compare clinician perspectives regarding deprescribing cardiovascular medications across three specialties. National cross-sectional survey. Ambulatory. Random sample of geriatricians, general internists, and cardiologists from the American College of Physicians. Electronic survey assessing clinical practice of deprescribing cardiovascular medications, reasons and barriers to deprescribing, and choice of medications to deprescribe in hypothetical clinical cases. In each specialty, 750 physicians were surveyed, with a response rate of 26% for geriatricians, 26% for general internists, and 12% for cardiologists. Over 80% of respondents within each specialty reported that they had recently considered deprescribing a cardiovascular medication. Adverse drug reactions were the most common reason for deprescribing for all specialties. Geriatricians also commonly reported deprescribing in the setting of limited life expectancy. Barriers to deprescribing were shared across specialties and included concerns about interfering with other physicians' treatment plans and patient reluctance. In hypothetical cases, over 90% of physicians in each specialty chose to deprescribe when patients experienced adverse drug reactions. Geriatricians were most likely and cardiologists were least likely to consider deprescribing cardiovascular medications in cases of limited life expectancy (all P < .001), such as recurrent metastatic cancer (84% of geriatricians, 68% of general internists, and 45% of cardiologists), Alzheimer dementia (92% of geriatricians, 81% of general internists, and 59% of cardiologists), or significant functional impairment (83% of geriatricians, 68% of general internists, and 45% of cardiologists). While barriers to deprescribing cardiovascular medications are shared across specialties, reasons for deprescribing, especially in the setting of limited life expectancy, varied. Implementing deprescribing will require improved processes for both physician-physician and physician-patient communication. J Am Geriatr Soc 68:78-86, 2019.
Sections du résumé
BACKGROUND/OBJECTIVES
Guideline-based management of cardiovascular disease often involves prescribing multiple medications, which contributes to polypharmacy and risk for adverse drug events in older adults. Deprescribing is a potential strategy to mitigate these risks. We sought to characterize and compare clinician perspectives regarding deprescribing cardiovascular medications across three specialties.
DESIGN
National cross-sectional survey.
SETTING
Ambulatory.
PARTICIPANTS
Random sample of geriatricians, general internists, and cardiologists from the American College of Physicians.
MEASUREMENTS
Electronic survey assessing clinical practice of deprescribing cardiovascular medications, reasons and barriers to deprescribing, and choice of medications to deprescribe in hypothetical clinical cases.
RESULTS
In each specialty, 750 physicians were surveyed, with a response rate of 26% for geriatricians, 26% for general internists, and 12% for cardiologists. Over 80% of respondents within each specialty reported that they had recently considered deprescribing a cardiovascular medication. Adverse drug reactions were the most common reason for deprescribing for all specialties. Geriatricians also commonly reported deprescribing in the setting of limited life expectancy. Barriers to deprescribing were shared across specialties and included concerns about interfering with other physicians' treatment plans and patient reluctance. In hypothetical cases, over 90% of physicians in each specialty chose to deprescribe when patients experienced adverse drug reactions. Geriatricians were most likely and cardiologists were least likely to consider deprescribing cardiovascular medications in cases of limited life expectancy (all P < .001), such as recurrent metastatic cancer (84% of geriatricians, 68% of general internists, and 45% of cardiologists), Alzheimer dementia (92% of geriatricians, 81% of general internists, and 59% of cardiologists), or significant functional impairment (83% of geriatricians, 68% of general internists, and 45% of cardiologists).
CONCLUSIONS
While barriers to deprescribing cardiovascular medications are shared across specialties, reasons for deprescribing, especially in the setting of limited life expectancy, varied. Implementing deprescribing will require improved processes for both physician-physician and physician-patient communication. J Am Geriatr Soc 68:78-86, 2019.
Identifiants
pubmed: 31509233
doi: 10.1111/jgs.16157
pmc: PMC7061460
mid: NIHMS1066381
doi:
Substances chimiques
Cardiovascular Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
78-86Subventions
Organisme : NIA NIH HHS
ID : R03 AG064373
Pays : United States
Organisme : NIA NIH HHS
ID : L30 AG060493
Pays : United States
Organisme : NIA NIH HHS
ID : R03 AG056446
Pays : United States
Organisme : NIA NIH HHS
ID : L30 AG060521
Pays : United States
Organisme : NIA NIH HHS
ID : K24 AG049057
Pays : United States
Organisme : NIA NIH HHS
ID : K76 AG059929
Pays : United States
Organisme : National Research Service Award training
ID : T32HP19025-14
Pays : International
Organisme : NIA NIH HHS
ID : R24 AG064025
Pays : United States
Informations de copyright
© 2019 The American Geriatrics Society.
Références
JAMA Intern Med. 2018 Dec 1;178(12):1673-1680
pubmed: 30326004
J Am Geriatr Soc. 2015 Nov;63(11):2227-46
pubmed: 26446832
J Am Coll Cardiol. 2019 May 28;73(20):2584-2595
pubmed: 31118153
Pharmacoepidemiol Drug Saf. 2011 May;20(5):514-22
pubmed: 21308855
BMC Fam Pract. 2012 Jul 09;13:56
pubmed: 22697490
N Engl J Med. 2007 Mar 15;356(11):1130-9
pubmed: 17360991
BMJ. 2016 Jun 03;353:i2893
pubmed: 27260319
Ann Intern Med. 2019 Jan 22;170(3):199-200
pubmed: 30665237
Can Fam Physician. 2017 May;63(5):354-364
pubmed: 28500192
N Engl J Med. 2018 Oct 18;379(16):1519-1528
pubmed: 30221595
JAMA. 2015 Nov 3;314(17):1818-31
pubmed: 26529160
BMJ Open. 2014 Dec 08;4(12):e006544
pubmed: 25488097
JAMA. 2018 Nov 13;320(18):1889-1898
pubmed: 30422193
J Gen Intern Med. 2014 Apr;29(4):594-601
pubmed: 24408277
Am J Manag Care. 2015 Apr;21(4):277-83
pubmed: 26014466
Age Ageing. 2017 Jul 1;46(4):600-607
pubmed: 28119312
Age Ageing. 2016 Jan;45(1):115-20
pubmed: 26683048
PLoS One. 2016 Aug 12;11(8):e0161248
pubmed: 27517450
JAMA Intern Med. 2015 May;175(5):827-34
pubmed: 25798731
Drugs Aging. 2016 Apr;33(4):249-66
pubmed: 26915076
Circ Cardiovasc Qual Outcomes. 2015 Nov;8(6):631-3
pubmed: 26487738
Eur J Clin Pharmacol. 2015 Jul;71(7):861-75
pubmed: 25967540
BMJ. 2018 Sep 5;362:k3359
pubmed: 30185425
Can Fam Physician. 2017 Nov;63(11):832-843
pubmed: 29138153
N Engl J Med. 2011 Nov 24;365(21):2002-12
pubmed: 22111719
Br J Clin Pharmacol. 2016 Sep;82(3):583-623
pubmed: 27077231
J Am Geriatr Soc. 2019 Feb;67(2):371-380
pubmed: 30536694
Eur J Intern Med. 2017 Mar;38:3-11
pubmed: 28063660
Ann Intern Med. 1987 Aug;107(2):169-73
pubmed: 2886086